S. Aamdal

Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients

Lijun Mu, Jon Amund Kyte, Gunnar Kvalheim et al. · British Journal of Cancer · 2005 · 113 citations · Full text

Dacarbazine–vindesine versus dacarbazine–vindesine–cisplatin in disseminated malignant melanoma. A randomised phase III trial

Ulf Jungnelius, Ulrik Ringborg, S. Aamdal et al. · European Journal of Cancer · 1998 · 60 citations

Oncology, Medicine, Disseminated Malignant Melanoma +8

Phase II study of E7070 in patients with metastatic melanoma

J F Smyth, S. Aamdal, Ahmad Awada et al. · Annals of Oncology · 2004 · 59 citations · Full text

Medicine, Melanoma, Metastatic Melanoma +4

Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b

Yvonne Brandberg, S. Aamdal, Lars Bastholt et al. · European Journal of Cancer · 2011 · 28 citations · Full text

Quality Of Life, High-risk Melanoma, Oncology +9

Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: A study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001)

Lothar Bergmann, S. Aamdal, Sandrine Marréaud et al. · European Journal of Cancer · 2008 · 21 citations

Advanced Cancer, European Organisation, R Viscumin +11